In clinical practice, undertreatment with intravitreal anti-vascular endothelial growth factor (VEGF) injections appear to be a key factor for continuing visual acuity loss in the treatment of neovascular age-related macular degeneration (nAMD).1 The gene discussed is VEGFA; the disease is wet macular degeneration.